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OBJECTIVES: To estimate the daily cost of intensive care unit (ICU) stay in France
using a microcosting methodology. METHODS: A multicentre prospective cost
analysis study was carried out among 23 French ICUs randomly selected from the
French National Hospital database stratified by hospital category (regional, univer-
sity and private non profit). Each ICU enrolled 5 adult patients admitted from May
to October, 2009, selected at random, with a simplified acute physiology score
(SAPSII)15 at admission and with at least 1 reanimation medical act. All health-
care resources used by each patient over a 24-hour period were recorded, as well as
the time spent by all hospital staff involved in the patient’s management. All re-
sources identified were valued from a hospital perspective (reference year 2009)
based on unit cost data provided by each centres. Bi-variant analyses were carried
out to identify potential cost-drivers. RESULTS: A total of 104 patients were en-
rolled by 21 ICUs (14 polyvalent, 3 surgical and 4 medical) were included. The mean
age of patients was 62.3 years (SD 14.9); 64% were male; 86% were mechanically
ventilated and the median Sequential Organ Failure Assessment (SOFA) score was
6 (SD 4.3). The average daily cost of ICU per patient was €1,424 (SD €520). Staff time
represented the largest component of this cost (43%) followed by overheads, capi-
tal, hotel and nutrition assigned to the ICU (22.9%). Medication and consumables
used accounted for 18.6% of the total cost. The majority of the cost (59%) was
patient-dependant. The two main patient-dependant factors associated with sig-
nificantly higher costs were: a high SOFA score and being on continuous mechan-
ical ventilation. CONCLUSIONS: This first French microcosting study in ICU dem-
onstrates that the cost per day of ICU care is substantially depends on the patient’s
medical profile and mainly driven by labour components.
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OBJECTIVES: Budget impact analysis (BIA) is a tool used to predict and understand
the potential financial impact of introducing a new health care intervention into a
health care system that has finite financial resources. Czech laws only prescribe
duty to attach BIAs to the applications for new drug reimbursements without spec-
ifying guidelines how to prepare BIA. We analyzed the differences between the BIA
in the applications and the real expenditures of the public health insurance.
METHODS: We have selected 3 applications of new drugs (romiplostin, lenalido-
mid, bevacizumab) submitted in year 2009 (or an established drug in new indica-
tion) and compared submitted BIA estimates for year 2010 with the real expendi-
tures in the same year. We also compared the methods in the submitted BIAs with
the Impact Analysis Guidelines published by Patented Medicine Prices Review
Board (Canadian National Drug Reimbursement Authority) to identify potential
reasons of differences. RESULTS: We found differences in the predicted number of
patients, average cost of drug application and total impact on the public health
insurance. CONCLUSIONS: The comparison with standard guidelines identified
the key areas to be addressed in the future Czech legislative to improve the quality
of submitted BIAs. The inaccuracies were mainly caused due to a) Lack of data
sources and their transparency; b) Inaccurate or misapplied assumptions; c) Inap-
propriate choice of comparators; and d) Overall quality, e.g. false interpretation of
referenced studies conclusions.
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EXPLORING DIFFERENT HRQOL MEASURES AS PREDICTORS OF FUTURE
HEALTH CARE EXPENDITURES
Gatwood J, Erickson S
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OBJECTIVES: To assess the relative ability of several health-related quality of life
(HRQOL) measures to predict future health care expenditures. METHODS: Data
from the Medical Expenditure Panel Survey (MEPS) for years 2003 (Panel 4, Round 2)
and 2004 were used for study purposes and weighted in order to gain a population-
level analysis. Applying the Model of Health Services Use, predisposing (age, gen-
der, race, years of education, and marital status) and enabling (insurance type,
employment status, family size, and annual household income) variables were
combined with varying need variables (SF-12 PCS, SF-12 MCS, EQ-5D Index, EQ-5D
VAS, single-item core questions of perceived physical and mental health status, or
a combination thereof) and used to predict overall healthcare expenditures, one
year after survey, in multivariate linear regression models. The individual R2 val-
ues were used for model comparison. RESULTS: The final dataset was composed of
9304 respondents, representing over 186 million US residents. The base model of
only predisposing and enabling covariates resulted in an R2 value of 0.067. The
model using both the SF-12 PCS and MCS values as need variables resulted in the
highest R2 value of all models run: 0.094. Use of the SF-12 MCS or the single-item
perceived mental health core item as need variables only marginally out-per-
formed the base model, both resulting in R2 values of 0.069. The EQ-5D VAS and
Index as well as the physical health perception core measure values were similar,
ranging from 0.0821 to 0.0868. CONCLUSIONS: The combined use of the SF-12 MCS
and PCS measures as need variables in the Model of Health Services Use performed
better than the other HRQOL measures in the MEPS dataset in predicting future
health care expenditures.
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CONVERGENT TENDENCIES IN BUDGET IMPACT ANALYSIS ACROSS EUROPE
AND BEYOND: GERMANY - DON’T LOSE OUT ON THE “ZEITGEIST”!
Bechtel B, Welte R
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OBJECTIVES: On January 1, 2011, the rapid benefit assessment (RPA) as basis for
central price regulations was introduced for new drugs in Germany. It requires the
pharmaceutical manufacturer to submit a value dossier. The objective was to in-
vestigate converging trends in budget impact analysis (BIA) requirements in se-
lected countries and to compare them to the German RPA. METHODS: We con-
ducted a systematic review of national guidelines on BIA requirements for the
pricing and reimbursement process of pharmaceuticals in 14 countries across the
western world (Europe, North America, Israel). Where needed informal stakeholder
interviews were used to supplement lacking information. The information was
extracted and evaluated based on 10 characteristics obtained from the “ISPOR
Principles of Good Research Practice for Budget Impact Analysis” (Mauskopf et al.
2007). RESULTS:All of the investigated countries except for Germany, Scotland and
Norway consider the direct medical budget impact of new pharmaceuticals in their
reimbursement decision making. In Germany, only the maximum annual direct
intervention costs have to be stated. Although Norway and Scotland request no BIA
from a payer’s perspective the drug’s impact on the change in medical resource
consumption is analyzed as part of the pharmacoeconomic and comparative ef-
fectiveness analyses. 8 countries demand a self-contained BIA complementary to
the broader health economic evaluation, while 3 countries deal with financial con-
sequences as part of the economic evaluation. In all countries except for Germany
economic consequences for the healthcare budget have to be presented for at least
2-5 years on an annual basis to capture medium to long term savings and expen-
ditures associated with changes in the medical resource utilization following a
drug’s availability in the market. CONCLUSIONS: All investigated countries except
Germany consider changes in the resource consumption and their financial con-
sequences (even for a medium term period) for decision making.
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OBJECTIVES: The efficient use of resources requires explicit criteria for setting
health care research priorities. We assessed whether economic evaluations of
healthcare interventions are directed to priority diseases in the allocation of pub-
lic-funded research in the Spanish National Health System. METHODS: We ana-
lyzed data from a systematic review of economic evaluations performed in Spain
(period 1983-2008). Reports were grouped according to the source of funding. We
included a representative sample of public funds allocated to research projects
(2006/2007 calls of the Instituto de Salud Carlos III, Spanish Ministry of Science and
Innovation). Both economic evaluations and research projects were classified ac-
cording to the main disease causes, following the classification proposed by the
World Health Organization in its Global Burden of Disease study. We calculated
Spearman correlation coefficients (r) between the public funds and economic
evaluations. RESULTS: A total of 1410 research projects (equivalent to €125.6 mil-
lion) and 477 economic evaluations were identified and could be categorized in 20
groups and 40 specific causes of diseases. For major groups (n20), the associations
were: total economic evaluations (r0.80, p 0.001), economic evaluations funded
by for-profit organizations (r0.77, p 0.001) and those funded by nonprofit orga-
nizations (r0.85, p 0.001). For specific disease-causes (n40): total economic
evaluations (r0.52, p0.001), economic evaluations funded by for-profit organiza-
tions (r0.38, p0.016) and funded by nonprofit agencies (r0.61, p0.001).
CONCLUSIONS: The distribution of priorities is similar between economic evalua-
tions and public research funds allocated to specific diseases. However, the optimal
level of these distributions could be determined with additional analyses on the
impact of research results in reducing the burden of disease in the population.
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WHERE A CHEAP MEDICINE IS NOT THE SAME AS A GENERIC MEDICINE: THE
BELGIAN CASE
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OBJECTIVES: The aim of this study is to describe the experience with the Belgian
policy that obliges physicians to prescribe minimum quota of cheap medicines and
to document the outcomes of this policy using publicly available data. METHODS:
Data were obtained from yearly feedback reports of the policy on the website of the
Belgian third-party payer (RIZIV/INAMI) which were sent to all physicians. Data
were derived from Farmanet, a database where all data of prescriptions of reim-
bursed medicines from all physicians in Belgium are collected. RESULTS: All
groups of general practitioners, specialists and dentists reached their minimum
percentages every year from 2006 until 2009. The percentage of cheap medicines (in
DDD) increased from 22.9% in January 2005 to 44.2% of all prescribed medicines in
ambulatory care in December 2009. The percentage of generic medicines increased
from 12.10% in 2004 to 24.03% of all prescribed medicines in ambulatory care in
2008. When a physician prescribed a cheap medicine, this was an original medicine
whose price had dropped to the reference price level in 41.5% of cases in August
2009. CONCLUSIONS: The policy of prescribing quota for cheap medicines was not
only associated with increased prescribing of generic medicines during 2004-2008,
but also increased prescribing of original medicines whose price had dropped to
the reference price level. The potential for prescribing generic medicines has not
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yet been fully met in Belgium. Despite the success of the policy, adjustments are
desirable, especially with respect to the broad definition of cheap medicines. Given
the fact that all groups of physicians reached their minimum quota quite easily
together with the increased possibility of prescribing cheap medicines due to the
entrance of new, generic medicines, the government decided to raise the minimum
criteria in 2011.
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OBJECTIVES: To analyze state funding sources of drug provision all over RF for the
period of 2009-2010. METHODS: Different sources of drug funds were summed up
during this research. All materials were taken from the open sources: results of
auctions of the federal and regional level, orders of the Ministry of Public Health
and Social Development, analysis of regional programs of the drug provision and
etc. RESULTS: Interactive map of the RF was developed due to this analysis of the
collected data, it shows information on each region of the RF, the number of priv-
ileges people, population of the region, sum of the budget by the ONLS (reimburse-
ment) programs, the sum of the budget according to the regional reimbursement,
sum of the hospital budgets, sum of the special programs of the region (if such
programs approved in the region), sum of the budget by the program “7 nosologies”
(special reimbursement program), with the detailed separation of the budget ac-
cording to the nosologies. Such map clearly demonstrates difference in the funding
system between regions. The ranges of color distinction by regions were put into
the map for more convenient usage, it allows visually demonstrate difference in
funding on the territory of the RF. Several pilot regions of the RF were chosen where
data was validated, this process showed complete conformity of the existing data
with the official budgets of the regions. CONCLUSIONS: Nowadays this research
represents unique product in acceptance of administrative decisions for the ad-
ministrators of health sector of the RF. Also for the further improvement of the
given analytical system it is necessary to adjust the collecting of the corresponding
data for 2011 and to analyze the budget of regions on the Federal Health Modern-
ization Program 2011-2012.
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OBJECTIVES:General public perceptions will affect on their behavior towards med-
icines. Therefore, this study aims to evaluate the general public perceptions to-
wards medicines in the state of Penang Malaysia. METHODS: A cross sectional
study using convenience sampling technique was used. Appropriate descriptive
and inferential statistics were used to find the differences among the respondents.
All data were analyzed at alpha value of 0.05. RESULTS: Seven hundred respon-
dents were successfully responded to the survey. More than one third of the re-
spondents 37% stated that they understand what is meant by conventional medi-
cines, whereas 18.6% understand traditional medicines and only 3% understand
what is meant by generic medicines. On the other hand, 36% see doctor once they
have minor illness and 30% prefer to go to get OTC drugs from the community
pharmacy. Furthermore, 62% believe that more expensive drugs are of better qual-
ity, and more than 50% believe that advertising affect on their perceived quality of
medicines as well as the country of the manufacturer affects on their selection of
the drugs. Previous experience, physician’s recommendations, pharmacist’s rec-
ommendations, friend’s recommendations, cost of the medicine and medical in-
surance coverage were the main factors that affect on their perceptions.
CONCLUSIONS: General public in Penang are very concerning about the medicine
chosen. General public education on various types of medicines is important to
correct misconceptions and give them the knowledge that they need to make an
informed decision. Hence, physicians, pharmacists and other health care providers
play vital roles in educating the general public about medicines.
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THE ECONOMIC BURDEN OF DISEASE RELATED MALNUTRITION IN EUROPE
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OBJECTIVES: Disease related malnutrition (DRM) is a frequent but often unrecog-
nised problem, even in the developed world. The objective of this study was to
estimate the burden of disease related malnutrition (BoDRM) in Europe.METHODS:
An Excel model was developed to estimate direct incremental health care costs and
health burden (including increased mortality and reduced quality of life) due to
DRM. The monetary value of the health burden was calculated by multiplying the
QALY loss with explicit or implicit (2x GDP/capita) cost effectiveness thresholds in
each country. Collection of input variables involved a wide spectrum of current
data sources: international databases, PubMed, congress abstracts, references
from published papers. Ten primary diseases were incorporated into the model:
stroke, breast cancer, COPD, dementia, depression, colorectal cancer, musculosk-
eletal disorders, head and neck cancer, coronary heart disease, chronic
pancreatitis. RESULTS: For the 835 million European citizens, the direct financial
BoDRM is over 31 billion EUR annually. The estimated annual health burden is
approximately 5.7 million life years or 9.1 million QALYs. The total monetary value
of the health and financial BoDRM is 306 billion EUR. The health burden in chronic
diseases is greater than in acute diseases, and is also greater than the financial
burden. In acute diseases, the financial burden is greater than the health burden.
CONCLUSIONS: In Europe, DRM is a considerable health and financial burden and
represents a significant contribution to the total burden of disease, estimated by
WHO to be 255 million DALYs annually. Therefore, there is a need to improve
nutritional care in all aspects of patient management. The availability of scientific
data on DRM is limited, especially regarding the relative mortality risk and quality
of life impact. Policy makers should support programmes to extend the clinical and
economic evidence base for nutritional care.
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OBJECTIVES:The inclusion of lost productivity costs in pharmacoeconomic studies
is still a subject of considerable debate. The aim of this study was to quantify the
work impairment due to general health status in population of employees and
employers (i.e. owners and managers). METHODS: Data were obtained from a sur-
vey that incorporated the WPAI-GH questionnaire and questions on costs of worker
replacement (including hiring and training process). The survey was conducted in
cooperation with Employers of Poland – the largest and oldest organisation of
employers in Poland in the framework of research grant no N N405 115034 offered
by the Ministry of Science and Higher Education of the Republic of Poland.
RESULTS: The non-representative population comprised 196 subjects in paid jobs
(156 employees and 40 employers), 167 of whom were currently employed in gov-
ernment-owned corporations (with 250 employees). Employees reported 7.4% of
work time missed due to health problems (absenteeism) during the past 7 days
(0.8% for employers; p0.052). Impairment while being at work (presenteeism)
amounted to 12.2% of total time for employers (5.4% for employers; p0,05). Per-
centage of overall work impairment due to health problems for employees and
employers were 5.7% vs. 18.3%, respectively (p0.05). On average more than 50% of
overall work impairment was compensated by other employees in the company
with a general tendency of a higher compensation of employees’ responsibilities.
Mean time of hiring and training new worker to achieve 50% of expected produc-
tivity was 76 days and 216 days to achieve full productivity. CONCLUSIONS: Pro-
ductivity loss measured by WPAI-GH is higher among employees than employers
in analyzed sample in Poland, with a tendency of a higher compensation among
employees. Preliminary data suggest that overall work impairment can be com-
pletely compensated within a one year from a single employer perspective and
support friction cost approach.
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OBJECTIVES: An automated dose dispensing (ADD) service is implemented in pri-
mary health care in some countries, particularly in the Nordic countries. In this
service, regularly used medicines are machine-packed into unit-dose bags for each
point of administration. The aim of this study is to review the evidence of the ADD’s
influence on the appropriateness of medication use, medication safety and costs in
the primary health care.METHODS:A literature search was performed on the most
relevant databases, including the Medline, Embase, and Cochrane Library. An ar-
ticle was included in the review if the study was conducted in primary health care
or nursing home settings and medicines were dispensed in unit-dose bags. All
study designs were approved and control groups were not required. Studies apply-
ing outcome measures that were related to the appropriateness of medication use,
medication safety or costs were included. RESULTS: Out of 278 abstracts, six stud-
ies were found to be acceptable. The prevalencies of potential inappropriate drug
use (IDU) were higher among ADD users than non-ADD users. After controlling for
confounding factors, ADD reduced the probability of long-acting benzodiazepine
use among women and drug-drug interactions among women and men. The ADD
users aged 65-79 years had more problems with potential IDU than older ones
(80 years). The risk of administration errors was lower if medicines were supplied
by the ADD service. The ADD service also reduced discrepancies in the documen-
tation of patient medication records. Any costs were not investigated in the
studies. CONCLUSIONS: The evidence of the influence of ADD on appropriateness
of medication use and medication safety is limited, and missing on costs. The
findings of this review suggest that the ADD service may improve medication
safety in primary health care, but does not effectively reduce potential IDU.
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INCORPORATING THE PATIENT PERSPECTIVE INTO THE HEALTH CARE
PROCESS: EXPERIENCE FROM THE C.A.T. HEALTH SYSTEM
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OBJECTIVES: To evaluate the feasibility of the C.A.T-Health system (a computer-
ized adaptive test which evaluates generic Health-Related Quality of Life-HRQoL) in
a university hospital, at different levels of the health care process. METHODS: The
C.A.T-Health system has been developed and validated within a 3 years research
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